HOME >> MEDICINE >> NEWS
Outstanding efficacy of Crestor (TM) in treating range of patient populations at risk of CVD

London, UK, 25 October 2004. New data presented today from several studies involving more than 5,000 patients provide further evidence of the outstanding efficacy of CRESTORTM (rosuvastatin) in treating key cardiovascular disease (CVD) risk factors in patients with dyslipidaemia and either atherosclerosis, coronary artery disease, type 2 diabetes or the metabolic syndrome.1-5

Results from five studies (DISCOVERY, COMETS, MERCURY I, URANUS, RADAR) presented at the XV International Symposium on Drugs Affecting Lipid Metabolism (DALM) demonstrate that CRESTOR is superior to atorvastatin in improving lipid profiles associated with an increased cardiovascular risk in a number of patient populations with dyslipidaemia.1-5 Results from MERCURY I and DISCOVERY also show that CRESTOR, at the usual start dose of 10mg, enables more patients achieve their US NCEP ATP III and European LDL-C goals, respectively, compared to atorvastatin 10mg, thereby avoiding the need to titrate to higher doses.1,3

In current clinical practice, LDL-C is the most widely recognised target for lowering patients' cardiovascular risk.6,7 Guideline cholesterol goals are an important tool to assist physicians in the management of cardiovascular disease worldwide. Recently revised evidence-based guidelines set a series of targets for LDL-C reduction, which vary according to the overall risk category of the patient; the higher the patient's risk of cardiovascular events, such as heart attack or stroke, the lower the LDL-C goal.7 However, many patients are not achieving their recommended LDL-C treatment guideline goals, suggesting that more intensive management with effective statin therapy is required.8,9 Results from one study of the global DISCOVERY Programme*, involving 911 'high risk' patients with hypercholesterolaemia, demonstrate that more patients achieve the European LDL-C guideline goal of <3mmol
'"/>

Contact: Caroline Howe
caroline.howe@shirehealthinternational.com
Shire Health International
25-Oct-2004


Page: 1 2 3

Related medicine news :

1. Outstanding UCLA undergraduates present research
2. Peto and Doll win King Olav Vs Prize for Outstanding Cancer Research
3. Outstanding scholars set to improve geriatric social work in U.S.
4. ZETIA(R) co-administered with fenofibrate provided complementary lipid lowering efficacy
5. Vioxx: An unequal partnership between safety and efficacy
6. Max daily OTC dose of acetaminophen shows efficacy comparable to Rx doses of naproxen for OA pain
7. Seroquel: New data show efficacy and tolerablity in bipolar depression
8. New drug for non-small cell lung cancer shows efficacy
9. Study highlights efficacy of sirolimus stents to prevent restenosis for PTS with CAD
10. Study finds obesity not associated with efficacy of tamoxifen for early-stage breast cancer
11. Landmark antidepressant analysis demonstrated significant efficacy of Effexor®/Effexor XR

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/17/2019)... ... September 17, 2019 , ... National University has ... American Heart Association (AHA)-San Diego Chapter to raise awareness of heart health. Meb ... Saturday, September 21 in Balboa Park alongside National University System Chancellor and AHA ...
(Date:9/17/2019)... ... September 17, 2019 , ... ... contributing to the long-term health of canines – specifically golden retrievers - through ... Retrievers will die from cancer – one out of five retrievers in the ...
(Date:9/17/2019)... (PRWEB) , ... September 17, 2019 , ... ... to join the largest accountable care organization (ACO) in the country, the company ... this groundbreaking collaboration to improve care quality and increase cost efficiency. This opportunity ...
(Date:9/17/2019)... ... September 17, 2019 , ... Dr. Perry Patel, ... been certified by the American Academy of Facial Esthetics (AAFE) to administer Botox ... range of orofacial conditions such as tooth clenching and grinding, tongue tension, temporomandibular ...
(Date:9/17/2019)... ... September 17, 2019 , ... The ... announce the release of the third edition of The Gift of Participation. Written ... patients, caregivers and families to navigate the clinical research process. The new edition ...
Breaking Medicine News(10 mins):
(Date:9/17/2019)... ... September 17, 2019 , ... Drs. ... and Medford, NJ, now welcome patients from Cherry Hill, NJ for tooth extractions, ... teeth whenever possible. When tooth removal is necessary, they use advanced equipment and ...
(Date:9/17/2019)... ... September 17, 2019 , ... Embr Labs , the ... Series B funding led by DigiTx Partners, with participation from Safar Partners, ... use the investment to grow the company’s footprint in wellness and digital therapeutics, accelerate ...
(Date:9/14/2019)... ... September 13, 2019 , ... ... for employers, became the first commercial teledentistry practice in the United States. Now, ... other hub entrepreneurs, company leaders, innovators and industry experts next week at CIC ...
Breaking Medicine Technology:
Cached News: